广济药业(000952.SZ)2020年上半年净利预降68.15%至75.32%
格隆汇7月9日丨广济药业(000952.SZ)发布2020年半年度业绩预告,预计归属于上市公司股东的净利润1550万元至2000万元,同比减少68.15%至75.32%;基本每股收益0.056元至0.072元。
报告期内,公司积极克服新冠疫情带来的不利影响,加大市场销售力度,公司主导产品销售量较去年同期增长,但因主导产品销售价格处于低价位水平,平均销售价格较去年同期下降,加之受新型冠状病毒肺炎疫情影响,处于被动停工状态,至2020年3月上旬全面启动复工复产,开工时间同比减少,导致单位成本增加,产品毛利率同比下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.